✦ LIBER ✦

Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

✍ Scribed by Justin B. Wenger; Napoleon Santos; Yanxia Liu; Jennifer Dallas; Sukanthini Subbiah; Steven Hochwald; Emina H. Huang; Duyen T. Dang; Carmen J. Allegra; Hendrik Luesch; Long H. Dang

Book ID: 107616050
Publisher: PAGEPress Publications
Year: 2011
Tongue: English
Weight: 251 KB
Volume: 5
Category: Article
ISSN: 1970-5557
DOI: 10.1007/s12156-011-0082-3

No coin nor oath required. For personal study only.

✦ Synopsis

Antiangiogenic therapy has shown promise in the treatment of patients with hepatocellular carcinoma (HCC). Bevacizumab, sorafenib, and sunitinib showed efficacy in patients with HCC; and sorafenib is approved by the FDA for treatment of this cancer. In practice, the clinical benefit of these agents has been heterogeneous; and in patients who do respond, the benefit is modest and/or short-lived. Recent advances in the molecular understanding of tumor angiogenesis along with the rapid development of targeted drug discovery have made it possible to explore novel combination therapy for HCC. We review the clinical trial results, discuss possible molecular mechanisms of resistance, and suggest novel combinations with antiangiogenic therapy.

📜 SIMILAR VOLUMES

Phase 1-2 trial of PTK787/ZK222584 combi

Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma : Implication for antiangiogenic approach to hepatocellular carcinoma

✍ Thomas Yau; Pierre Chan; Roberta Pang; Kelvin Ng; S. T. Fan; Ronnie T. Poon 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB

## Abstract ## BACKGROUND: This phase 1‐2 trial assessed the efficacy and tolerability of an oral angiogenesis inhibitor—PTK787/ZK222584 (PTK)—in combination with intravenous doxorubicin for the treatment of advanced hepatocellular carcinoma (HCC) patients. ## METHODS: In phase 1, advanced HCC p

Can we expand the indications for liver

Can we expand the indications for liver transplantation among hepatocellular carcinoma patients with increased tumor size?

✍ J.A Fernández; R Robles; C Marin; F Sánchez-Bueno; P Ramirez; J.A Pons; M.C Garr 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Percutaneous radiofrequency ablation the

Percutaneous radiofrequency ablation therapy with combined angiography and computed tomography assistance for patients with hepatocellular carcinoma

✍ Takahiro Yamasaki; Fumie Kurokawa; Hitoshi Shirahashi; Noriyoshi Kusano; Kouji H 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 1 views

## BACKGROUND. Radiofrequency ablation (RFA) for patients with hepatocellular carcinoma (HCC) has been reported previously. This technique is superior to percutaneous microwave coagulation therapy (PMCT) for the enlargement of the necrotic area. Therefore, a few treatment sessions of RFA for patie

Combination Therapy of Radiofrequency Ab

Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization Provides Survival Benefit for Patients With Unresectable Hepatocellular Carcinoma

✍ C.L. Marshall; S.T. Orcutt; C.N. Robinson; C.J. Balentine; C. Bechara; P. Kougia 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Long-Term Results of Hepatic Resection C

Long-Term Results of Hepatic Resection Combined with Intraoperative Local Ablation Therapy for Patients with Multinodular Hepatocellular Carcinomas

✍ Shinji Itoh; Kazutoyo Morita; Shigeru Ueda; Keishi Sugimachi; Yo-ichi Yamashita; 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 245 KB

408 RISK FACTORS FOR DEVELOPMENT OF HEPA

408 RISK FACTORS FOR DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CHRONIC HEPATITIS C AFTER SUSTAINED RESPONSE TO PEGINTERFERON AND RIBAVIRIN COMBINATION THERAPY

✍ K.-C. Chang; T.-H. Hu 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 40 KB